Natural History of Lung Cancer Diagnosed Within and Across Diverse Health Systems Implementing Lung Cancer Screening

实施肺癌筛查的不同卫生系统内部和之间诊断出的肺癌的自然史

• 批准号: 10687017
• 负责人: Nikki Carroll
• 金额: $ 15.02万
• 依托单位: KAISER FOUNDATION RESEARCH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-08-10 至 2025-07-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10687017
• 关键词: Award; Cancer Detection; Cancer Patient; Clinical; Clinical Trials; Colorado; Doctor of Philosophy; Foundations; Funding; Future; Genomics; Goals; Health; Health system; Journals; Malignant Neoplasms; Malignant neoplasm of lung; Manuscripts; Natural History; Peer Review; Productivity; Recurrence; Regimen; Research; Risk; Specialist; Time; Translational Research; Treatment outcome; Treatment-Related Cancer; Work; anticancer research; cancer care; cancer diagnosis; cancer therapy; career; community setting; individualized medicine; lung cancer screening; meetings; prognostic; screening; treatment choice; treatment pattern; treatment risk

Project Summary/Abstract The goal of this application is to support Nikki Carroll, MS, as a Research Specialist and Biostatistician at Kaiser Permanente Colorado Institute for Health Research. She supports the Cancer and Genomics Research Core under the direction of Debra Ritzwoller, PhD. The core of Ms. Carroll’s productive and successful career as a Research Specialist and Biostatistician is in cancer related treatment patterns and outcomes. This Research Specialist award would allow 5 years of funding to maintain protected time for Ms. Carroll to work exclusively on supporting and leading cancer research aimed at generating real-world evidence on cancer care that occurs outside of clinical trials. In particular, she will study the treatment patterns and risk of recurrence among those with screen detected lung cancer compared to lung cancers diagnosed outside of screening. These results could impact prognostic estimates, treatment choices, and future trials to develop tailored treatment and surveillance regimens for early-stage, screen-detected lung cancer patients and set the foundation for future studies of the natural history of lung cancer screening in community settings. Results will be broadly disseminated through local and national meetings as well as peer-reviewed journal manuscripts.

项目总结/摘要 此应用程序的目标是支持尼基卡罗尔，MS，作为一个研究专家， 凯泽永久科罗拉多健康研究所的生物统计学家。她支持 癌症和基因组学研究核心在黛布拉Ritzwoller博士的指导下。的核心 女士卡罗尔的生产和成功的职业生涯作为一个研究专家和生物统计学家是在 癌症相关的治疗模式和结果。该研究专家奖将允许5 多年的资金，以保持保护的时间，卡罗尔女士专门工作的支持和 领先的癌症研究，旨在产生现实世界的证据，对癌症护理发生 在临床试验之外。特别是，她将研究治疗模式和复发风险 在那些筛查出肺癌的人中， 筛选这些结果可能会影响预后估计，治疗选择和未来的试验 为早期筛查发现的肺结核制定量身定制的治疗和监测方案， 为肺癌自然史的未来研究奠定了基础 在社区进行筛查。结果将通过地方和 国家会议以及同行评审的期刊手稿。

项目成果

Individuals Eligible for Lung Cancer Screening Less Likely to Receive Screening When Enrolled in Health Plans With Deductibles.

有资格进行肺癌筛查的个人在加入具有免赔额的健康计划时接受筛查的可能性较小。

• DOI: 10.1097/mlr.0000000000001903
• 发表时间: 2023
• 期刊: Medical care
• 影响因子: 3
• 作者: Wain,Kris;Carroll,NikkiM;Honda,Stacey;Oshiro,Caryn;Ritzwoller,DebraP
• 通讯作者: Ritzwoller,DebraP

Percentage Up to Date With Chest Computed Tomography Among Those Eligible for Lung Cancer Screening.

符合肺癌筛查资格的人中接受最新胸部计算机断层扫描的百分比。

• DOI: 10.1016/j.amepre.2023.01.002
• 发表时间: 2023
• 期刊: American journal of preventive medicine
• 影响因子: 5.5
• 作者: Burnett-Hartman,AndreaN;Carroll,NikkiM;Croswell,JenniferM;Greenlee,RobertT;Honda,StaceyA;Neslund-Dudas,ChristineM;Kim,RogerY;Rendle,KatharineA;Vachani,Anil;Ritzwoller,DebraP
• 通讯作者: Ritzwoller,DebraP

Evaluation of Population-Level Changes Associated With the 2021 US Preventive Services Task Force Lung Cancer Screening Recommendations in Community-Based Health Care Systems.

• DOI: 10.1001/jamanetworkopen.2021.28176
• 发表时间: 2021-10-01
• 期刊: JAMA network open
• 影响因子: 13.8
• 作者: Ritzwoller DP;Meza R;Carroll NM;Blum-Barnett E;Burnett-Hartman AN;Greenlee RT;Honda SA;Neslund-Dudas C;Rendle KA;Vachani A
• 通讯作者: Vachani A

Uptake of novel systemic therapy: Real world patterns among adults with advanced non-small cell lung cancer.

• DOI: 10.1016/j.ctarc.2023.100730
• 发表时间: 2023
• 期刊: Cancer treatment and research communications